Colgate-Palmolive 10-Qquarter ended 2026-09-30

Executive Summary

Colgate-Palmolive earns revenue selling oral, personal and home care products to consumers and pet nutrition products to pet owners through retailers and professional channels. It is investing more in advertising, growing Hill’s therapeutic and wellness offerings, and reshaping its organization and supply chain to support its 2030 strategy. Q3 underlying sales growth improved, led by Latin America and Hill’s, but North America remained weak and restructuring charges depressed year-to-date earnings. The opportunity is to turn brand investment and cost savings into sustained volume growth; the threat is that soft consumer demand and materials inflation absorb those gains.

What's Happening in the Business

Growth was geographically uneven. Brazil, Argentina and Colombia led Latin America, while North America’s decline included both Personal Care and Oral Care. Europe, Middle East and Africa slowed materially against its year-to-date performance. Management expects category softness to persist through 2026, making stronger growth in selected markets more important than a broad consumer recovery.

Hill’s growth came from therapeutic and wellness products in the U.S. and Europe. Lower private-label pet-food sales partly offset that progress, reducing company-wide organic growth by 20bp in Q3. Prime100, acquired in 2025, also extends Hill’s into Australian fresh pet food, although significant materials-cost pressure is limiting profit growth.

Management expanded its Strategic Growth and Productivity Program in April to improve organizational alignment, supply-chain flexibility and overhead efficiency. It expects $200M–$300M of annualized pretax savings against $350M–$550M of total pretax charges, with substantially all charges incurred by 12/31/2028. Cumulative charges reached $346M; 80%–90% of total charges are expected to require cash, so the benefits come with substantial upfront spending.

Key Financial Highlights

• Organic growth: Q3 3.6% vs 9M 3.0%, with quarterly volume growth of 1.7% and pricing of 2.0%. Currency contributed 1.0% in Q3 vs 2.8% for 9M, explaining why reported and underlying growth moved differently.
• Regional drivers: Latin America’s organic growth was 6.0%; Hill’s was 5.7%. North America declined 1.6% organically. Europe, Middle East and Africa’s reported growth slowed from 5.4% for 9M.
• Gross margin and investment: Q3 margin reached 60.2%, up 80bp. Savings contributed 290bp, nearly offsetting 300bp of materials inflation; pricing added 80bp. Advertising rose 15% to $775M in Q3 and 13% to $2.29B for 9M.
• Costs outside segments: Corporate operating losses widened to $221M from $189M in Q3 and $902M from $523M for 9M, including program charges of $29M and $327M, respectively. Separately, 9M currency-contract losses were $81M vs $110M of gains, adding expense as hedges changed value.
• Cash generation: 9M operating cash flow rose 6.1% to $2.91B; after $400M of capital spending, free cash flow rose 6.6% to $2.51B. Cash flow exceeded earnings partly because depreciation and amortization of $470M reduced profit without current cash spending; receivables and inventory absorbed $328M, partly offset by $254M from payables and other working capital.
• Per-share results: Q3 diluted EPS rose 3.3% to $0.94 as diluted shares fell 1.3%; 9M EPS declined 2.2% to $2.61.

Risk Assessment

• Consumer demand and competition: Persistent category softness and consumer trade-down could prolong North American weakness and reduce returns on increased advertising.
• International and input exposure: Approximately two-thirds of sales come from outside the U.S. and 45% from emerging markets, exposing earnings to currency, tariff and geopolitical disruption alongside materials inflation.
• Restructuring execution: The program requires substantial cash spending before its full savings emerge; poor execution could disrupt supply or leave overhead reductions insufficient.
• Litigation and tax: Talc cases increased to 561 from 453 at year-end, while reasonably possible litigation losses beyond accruals reach ≈$225M; disputed tax assessments create additional potential period-specific charges.

A 10-Q does not have to restate the risk factors in the annual report. Full list: the company's 10-Ks on SEC.

What to Watch

• North American recovery: Organic sales declined 1.6%; stabilization in Oral Care and Personal Care would support the brand-investment case, while further contraction would undermine it.
• Hill’s branded growth: Therapeutic and wellness products are growing; continued sales growth with stronger profit growth would show pricing and savings overcoming materials pressure.
• Productivity delivery: Track management’s savings ambition against cash charges; success means better profitability without weakening sales or supply execution.